Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, today announces it has been granted a US patent for NOSO-502. NOSO-502 is Nosopharm’s first clinical candidate in a new class of...
PHILAGRO France, NICHINO Europe and AMOEBA have signed a development contract (MTA: Material Transfer Agreement) to evaluate the performance of the biocontrol fungicide containing AMOEBA’s active substance: the amoeba lysate Willaertia magna C2c Maky. Complete...
Recent Comments